1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Harbin Medisan Pharmaceutical Co., Ltd. Class A

Harbin Medisan Pharmaceutical Co., Ltd. Class A

SSZSE:002900
10.29
CNY
+0.04
(+0.39%)
-0.74EPS
2.90BMarket Cap
Harbin Medisan Pharmaceutical Co., Ltd. Class A
SZSE:002900
(Shenzhen Stock Exchange)

Recent

price

10.29

P/E

ratio

- -

div

yld

2.84%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
31.47
2.69
2.94
3.04
3.21
4.5
6.86
6.76
4.11
3.05
3.4
3.87
3.67
2.49
2.6
Revenue per Share
5.3
0.47
0.63
0.7
0.74
0.71
0.65
0.57
0.09
1.13
0.1
0.24
0.19
-1.07
-0.73
Basic EPS, GAAP
- -
- -
-0.13
0.25
0.58
0.46
0.68
0.39
-0.46
-0.28
0.18
-0.86
-1.02
-0.89
- -
Free Cash Flow per Basic Share
0.3
0.19
0.23
0.23
0.39
0.36
0.34
0.67
0.29
0.11
0.36
0.13
0.34
0.35
0.29
Dividend per Share
1.41
1.54
2.57
3.07
3.4
5.8
6.14
5.79
5.61
6.64
6.45
6.76
6.83
5.6
5.46
Book Value per Share
1.11
1.26
2.29
2.8
3.15
5.61
5.88
5.54
5.37
6.41
6.22
6.31
6.34
5.02
4.88
Tangible Book Value per Share
16
224
232
238
237
255
317
311
326
311
302
307
309
317
325
Basic Weighted Avg Shares
491
601
682
722
761
1,149
2,173
2,102
1,339
946
1,028
1,187
1,132
789
846
Sales/Revenue/Turnover
23.24
24.35
24.61
25.31
27.12
20.25
9.92
9.9
4.56
-13.62
-1.62
1.44
4.45
-34.87
-25.14
Operating Margin (%)
- -
- -
36
47
58
69
74
79
80
99
107
109
111
143
- -
Depreciation Expense
83
104
147
166
175
181
206
177
29
351
30
74
59
-340
-239
Net Income, GAAP
15.09
14.63
15.77
16
16.23
28.44
17.95
23.82
19.68
22.78
33.87
13.88
8.38
- -
- -
Effective Tax Rate (%)
16.84
17.36
21.57
23.03
23.02
15.76
9.47
8.43
2.19
37.11
2.94
6.21
5.18
-43.02
-28.21
Profit Margin (%)
-25
-116
33
57
68
1,092
1,194
962
844
891
1,026
591
214
-149
-300
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
11
213
423
238
139
277
141
LT Debt
343
365
609
728
808
1,835
1,966
1,852
1,792
2,116
2,052
2,148
2,164
1,775
1,730
Total Equity
- -
21.1
21.99
20.29
18.58
12.88
10.54
8.54
1.38
15.05
1.02
2.45
1.91
- -
- -
Return on Invested Capital (%)
- -
24.19
25.44
22.4
20.68
13.43
10.82
9.15
1.92
15.48
1.84
3.48
3.04
- -
- -
Return on Capital (%)
- -
29.78
30.17
24.87
22.81
13.7
10.89
9.38
1.63
18.11
1.46
3.52
2.73
-17.27
-12.36
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
842
713
752
LT Borrowings
273
313
139
LT Finance Leases
4
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
316
316
316
Market Capitalization
3,942
3,730
2,904

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
996
891
787
Cash, Cash Equivalents & STI
612
488
387
Accounts Receivable, Net
75
95
93
Inventories
237
237
251
Total Current Liabilities
1,146
1,012
1,087
Payables & Accruals
- -
- -
- -
ST Debt
842
713
752
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.87%
0.5%
-17.99%
Free Cash Flow
-84.1%
-154.63%
-10%
Net Income, GAAP
37.51%
90.01%
-678.82%
Sales/Revenue/Turnover
6.58%
-8.02%
-30.29%
Total Cash Common Dividend
37.92%
50.45%
5.47%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
247
277
315
294
1,132
2025
205
208
- -
209
789
2026
229
200
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.02
0.05
0.06
0.19
2025
-0.09
-0.2
- -
-0.41
-1.07
2026
-0.02
-0.12
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.28
0.02
0.02
0.34
2025
0.07
0.23
- -
0.02
0.35
2026
0.02
0.02
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) engages in the research, development, production, and sale of chemical pharmaceutical preparations, specialty active pharmaceutical ingredients (APIs), and medical devices primarily in China. Founded in 1996 and headquartered in Harbin, China, the company operates as a national high-tech enterprise with a focus on multiple dosage forms including tablets, injections, and infusions for domestic and foreign markets; its core products encompass nervous system drugs such as mirtazapine tablets, olacetam injections, piracetam injections, and injectable brain protein hydrolysate (III); cardiovascular treatments including edaravone injections, ligustrazine hydrochloride for injection, esprolol hydrochloride for injection, pentoxifylline injections, and sodium ferulate; musculoskeletal therapies like injectable bone peptides, loxicam for injection, and sodium osteopeptide chloride injections; anti-infectives such as rifamycin sodium for injection and clindamycin phosphate injection; basic and nutritional infusions including sodium chloride injection, glucose injection, alanyl glutamine injection, hydroxyethyl starch 130/0.4 sodium chloride injection, and compound amino acid injection (18AA-III); as well as metabolism drugs like methylcobalamin injection and others including valsartan dispersible tablets and sarcosinopeptide for injections. The company targets healthcare providers and patients across various therapeutic segments with approximately 2,522 employees and maintains GMP-certified facilities for lyophilized powders, small-volume injections, and large-volume infusions. In recent developments, Harbin Medisan Pharmaceutical's diltiazem hydrochloride injection and potassium chloride and sodium chloride injection pass consistency evaluations for generic drug quality and efficacy; it secures approvals for new products including triptorelin acetate injection in September 2024 and potassium chloride injection in May 2024; and reports operating revenue growth in its 2025 semi-annual results amid a focus on innovative pharmaceuticals and commercial insurance pathways.